AVITA Medical

Aging Global Population And Tech Advances Will Transform Wound Care

AnalystHighTarget

Not Invested

Community Contributor

Published

21 Aug 25

AnalystHighTarget's Fair Value

US$14.10

71.8% undervalued

11 Sep

US$3.97

-60.8%

-0.5%

-60.8%

-0.5%

You can edit this narrative until Aug 21 9:39 PM. Then, changes will post as Updates.

Author's Valuation

US$14.171.8% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$14.1

71.8% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

29.87%

Biotech revenue growth rate

9.24%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.48%

Calculation

US$181.08m

Earnings '28

2.68x

PE Ratio '28

US$484.44m

Market Cap '28

US$484.44m

Market Cap '28

27.86m

No. shares '28

US$17.39

Share Price '28

US$17.39 Share Price '28

Discounted to 2025 @ 7.24% p.a.

US$14.10

Fair Value '25